AYAs With Hematologic Malignancies Have Higher Risk of Early Death
The risk of early death in AYAs with cancer depends on the type of malignancy they have as well as multiple demographic factors, a study suggests.
Diagnosis & Disease Information
ICC Recategorization Facilitates Risk Stratification of Myelodysplastic Syndrome
A distinct mutational landscape and worse outcomes were seen for patients with MDS/AML vs those with MDS.
Brukinsa Gains Approval for Chronic Lymphocytic Leukemia
The approval was based on data from the phase 3 SEQUOIA and ALPINE studies in patients with CLL/SLL.
Posoleucel Deemed Effective Against Viral Infections in Allogeneic HSCT Recipients
Posoleucel appears safe and effective for treating refractory viral infections occurring after allogeneic hematopoietic stem cell transplant.
AstraZeneca Will Withdraw Lumoxiti From US Market
Lumoxiti was approved by the FDA in September 2018 for the treatment of adults with relapsed or refractory hairy cell leukemia.
Hispanic Patients May Have Increased Risk of CRS After CAR T-Cell Therapy
Researchers sought to determine whether race, ethnicity, or BMI would have an impact on CAR T-cell therapy outcomes in patients with B-ALL.
Olverembatinib Shows Promise in TKI-Resistant CML and Ph+ ALL
Olverembatinib has demonstrated antitumor activity in patients with chronic myeloid leukemia or Ph+ acute lymphoblastic leukemia.
Delaying HSCT More Than 4 Weeks After COVID-19 Diagnosis May Decrease Risk of Death
Undergoing HSCT within 4 weeks of SARS-CoV-2 infection is associated with an increased risk of death at 90 days after HSCT, real-world data suggest.
AML Research From ASH 2022: Novel Combinations and Evidence That “Less is More”
AML research presented at ASH 2022 highlighted promising combination regimens and suggested that some patients may benefit from less intensive treatment.
CAR-T Therapy in Pediatric Leukemia: Past, Present, and Future
Prior to the introduction of CAR T-cell therapy, pediatric patients with ALL had limited treatment options for relapsed or refractory disease.
- Loading...
Loading...
Next post in Hematologic Cancers
Loading... 
Loading...